Pipeline

Four programs. One gut-first strategy.

You need differentiated metabolic assets with a clear de-risking story. Each ApaisBio program is designed to act in the gut, and each moves forward only when it clears a gate.

Program descriptions reflect goals and design intent, not demonstrated results.

01 / Gated path

A gated path from discovery to a partner

Every step is a go/no-go decision. We plan to advance each program through preclinical de-risking and then license it to a pharmaceutical partner (see our model).

  1. 01Discover (in silico)
  2. 02Confirm (in vitro)
  3. 03Preclinical (in vivo)
  4. 04Partner and license

02 / The portfolio

Where each program stands today

  • 01

    Weight loss

    Lead franchise: gut-restricted polypharmacology

    Early mouse readout

    An oral molecule designed to help people feel satisfied sooner and eat less, by engaging several connected appetite signals locally in the gut.

    Preclinical (early in vivo)
  • 02

    Metabolic tuning

    Support healthier metabolism beyond the number on the scale, such as preserving lean mass and supporting healthy fat metabolism and energy balance.

    Discovery (in silico)
  • 03

    Gut inflammation

    Calm inflammation locally in the gut lining while limiting exposure elsewhere in the body.

    Discovery (in silico)
  • 04

    Gut-brain axis

    Tune the messages the gut sends to the brain about hunger and fullness, working from the gut side.

    Discovery (in silico)

03 / Lead franchise

Gut-restricted polypharmacology for weight loss

Appetite isn't one switch, so our lead program isn't built around one. The molecule is designed to be taken by mouth, to stay in the gut, and to engage several connected signals that help you feel full. Our goal is weight loss that people can sustain, with fewer of the side effects that cause many to stop treatment.

Early signal

In an early acute study in lean mice, one oral dose was followed by about 40% lower 6-hour food intake versus controls.

One small study; hypothesis-generating. Charts and caveats below.
Preclinical data Early mouse readout (preclinical) One small study in lean mice: food intake, activity, and body mass over 6 hours

Please read first. Early acute preclinical study in lean mice (n=4 dosed vs n=6 controls). Hypothesis-generating; not efficacy, not human data, not medical advice. Not yet peer reviewed.

The question was narrow: after one oral dose, do lean mice eat less once food returns after a fast? Food intake, body mass, and activity were tracked automatically in metabolic cages for 6 hours.

Food intakeDosed mice ate less
Cumulative food intake over 6 hours, mean plus or minus SEM Two lines rise from zero after food returns. Controls (n=6) reach 1.075 grams at 6 hours; dosed mice (n=4) reach 0.649 grams, about 40% lower. Shaded bands show the standard error of the mean. 0 0.25 0.5 0.75 1 1.25 0 1 2 3 4 5 6 Hours after food returned Food intake (g) Controls1.075 g Dosed0.649 g
Cumulative food intake (g), mean ± SEM
HourControls (n=6)Dosed (n=4)
1 h0.294 ± 0.0820.181 ± 0.045
2 h0.380 ± 0.0810.255 ± 0.056
3 h0.533 ± 0.1330.355 ± 0.066
4 h0.705 ± 0.1080.478 ± 0.078
5 h0.869 ± 0.1550.551 ± 0.096
6 h1.075 ± 0.1240.649 ± 0.065

At 6 h: 0.649 g vs 1.075 g cumulative intake, about 40% lower. All 4 dosed mice ate less than all 6 controls.

Mean ± SEM; shaded bands show SEM.

ActivitySame first-hour burst; no sign of sedation
Locomotor activity by hour after food returned, mean plus or minus SEM In the first hour both groups show a similar activity burst: dosed 4.9 and controls 5.2 meters per hour. In later hours dosed mice moved less on average; differences were not statistically resolved. 0 2 4 6 0–1 1–2 2–3 3–4 4–5 5–6 Hour after food returned Activity (m/h)
Locomotor activity (m/h), mean ± SEM
HourControls (n=6)Dosed (n=4)
0–1 h5.2 ± 0.54.9 ± 0.9
1–2 h2.1 ± 0.71.2 ± 0.5
2–3 h2.2 ± 0.50.9 ± 0.2
3–4 h2.4 ± 1.11.0 ± 0.4
4–5 h1.3 ± 0.41.3 ± 0.4
5–6 h3.4 ± 1.51.3 ± 0.7

First hour: 4.9 vs 5.2 m/h. Both groups showed the same burst of activity when food returned.

Mean ± SEM; first hour highlighted. Afterward, dosed mice moved less on average as they ate less (0–6 h mean 1.8 vs 2.8 m/h, not statistically resolved). Over the full multi-day run, activity showed no sustained separation.

Body mass

Body-mass regain after the fast trended lower in dosed mice (+0.57 g vs +1.14 g at 6 h). The difference was smaller than for intake and was not statistically resolved.

What this study does not show

It was not designed to show how the molecule works, whether the effect lasts, or whether it leads to weight loss. Two additional dosed mice with presumed capsule failures were excluded after the study; with them included, 6-hour intake did not differ between groups.

Next steps, each a go/no-go gate

  1. 01Acid stability
  2. 02Liability screens
  3. 03Diet-induced obesity study

Study reports are available to qualified partners under confidentiality and other agreements.

04 / Portfolio aim

Our aim is a portfolio, not a single product: programs that we hope could one day serve people across the spectrum, from modest, near-term goals to bariatric-level need, and that pharma partners can combine with, or offer alongside, existing therapies.

Want to look under the hood?

Study reports and program detail are shared with qualified partners under a confidentiality agreement.

Partnering and investment inquiries

Contact ApaisBio

Let's start a conversation.

Partnering, licensing, investment, or research collaboration. Only your email is required.

Please send information about